A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer.

ABSTRACT:

Background

EGFR and Src are frequently activated in non-small cell lung cancer (NSCLC). In preclinical models, combining EGFR and Src inhibition has additive synergistic effects. We conducted a phase I/II trial of the combination of Src inhibitor dasatinib with EGFR inhibitor erlotinib to determine the maximum tolerated dose (MTD), pharmacokinetic drug interactions, biomarkers, and efficacy in NSCLC.

Methods

The phase I 3+3 dose-escalation study enrolled patients with solid tumors to determine the MTD. The phase II trial enrolled patients with advanced NSCLC who had undergone no previous treatments to determine progression-free survival (PFS) and response. Pharmacokinetic and tissue biomarker analyses were performed.

Results

MTD was 150 mg of erlotinib and 70 mg of da

SUBMITTER: Gold KA 

PROVIDER: S-EPMC4201000 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature